Valerio Conti

Dr. Valerio Conti

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in JAMA Neurology
Verified
Journal Article
Open access
PDF file
GMGhayda Mirzaa
Ghayda Mirzaa
CCCatarina D. Campbell
Catarina D. Campbell
NSNadia Solovieff
Nadia Solovieff
CGCarleton P. Goold
Carleton P. Goold
LJLaura A. Jansen
Laura A. Jansen
WDWilliam B. Dobyns
William B. Dobyns
Focal cortical dysplasia (FCD) is a malformation of cortical development found in almost half of children referred for epilepsy surgery, making it the most frequent known cause of intractable focal epilepsy.1 The histopathologic changes that define FCD type 2 (FCD2) include cortical dyslamination and large dysmorphic neurons without (type 2a) or with (type 2b) balloon cells.2 Functional defects in the phosphatidylinositol 3-kinase (PI3K)–AKT (serine/threonine kinase, also known as protein kinase B)–mammalian target of rapamycin (mTOR) pathway have been demonstrated by Western blot, immunohistochemical staining, and AKT kinase and RNA expression analyses,3-5 and mutations of DEPDC5 (OMIM 614191), PTEN (germline) (OMIM 601728), and PIK3CA (postzygotic or mosaic) (OMIM 171834) have been found in FCD, classified as FCD1 or FCD2.3,6-13 Furthermore, 3 previous studies14-16 reported mosaic mutations in MTOR in patients with FCD2. Many studies2,3,6,17-19 have found links among diffuse megalencephaly, hemimegalencephaly, and FCD2, which have historically been considered distinct disorders. A link is further supported by discovery of germline or mosaic mutations of the same genes in the PI3K-AKT-mTOR pathway in patients with megalencephaly, hemimegalencephaly, or FCD. These data suggest that further genetic studies of FCD, as well as hemimegalencephaly and megalencephaly, are warranted to define additional genetic causes and explore links between the phenotypes and the levels and distribution of mosaic mutations.

7 May 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ICIrene Costantini
Irene Costantini
JGJean-Pierre Ghobril
Jean-Pierre Ghobril
AGAntonino Paolo Di Giovanna
Antonino Paolo Di Giovanna
AMANNA LETIZIA MASCARO
ANNA LETIZIA MASCARO
LSLudovico Silvestri
Ludovico Silvestri
FPFrancesco Saverio Pavone
Francesco Saverio Pavone
Extensive mapping of neuronal connections in the central nervous system requires high-throughput µm-scale imaging of large volumes. In recent years, different approaches have been developed to overcome the limitations due to tissue light scattering. These methods are generally developed to improve the performance of a specific imaging modality, thus limiting comprehensive neuroanatomical exploration by multi-modal optical techniques. Here, we introduce a versatile brain clearing agent (2,2′-thiodiethanol; TDE) suitable for various applications and imaging techniques. TDE is cost-efficient, water-soluble and low-viscous and, more importantly, it preserves fluorescence, is compatible with immunostaining and does not cause deformations at sub-cellular level. We demonstrate the effectiveness of this method in different applications: in fixed samples by imaging a whole mouse hippocampus with serial two-photon tomography; in combination with CLARITY by reconstructing an entire mouse brain with light sheet microscopy and in translational research by imaging immunostained human dysplastic brain tissue.

1 February 2019 in Genetics in Medicine
Verified
Journal Article
Open access
PDF file
SBSara Baldassari
Sara Baldassari
FPFabienne Picard
Fabienne Picard
NVNienke E. Verbeek
Nienke E. Verbeek
MKMarjan van Kempen
Marjan van Kempen
EBEva H. Brilstra
Eva H. Brilstra
SBStéphanie Baulac
Stéphanie Baulac
To define the phenotypic and mutational spectrum of epilepsies related to DEPDC5, NPRL2 and NPRL3 genes encoding the GATOR1 complex, a negative regulator of the mTORC1 pathway We analyzed clinical and genetic data of 73 novel probands (familial and sporadic) with epilepsy-related variants in GATOR1-encoding genes and proposed new guidelines for clinical interpretation of GATOR1 variants. The GATOR1 seizure phenotype consisted mostly in focal seizures (e.g., hypermotor or frontal lobe seizures in 50%), with a mean age at onset of 4.4 years, often sleep-related and drug-resistant (54%), and associated with focal cortical dysplasia (20%). Infantile spasms were reported in 10% of the probands. Sudden unexpected death in epilepsy (SUDEP) occurred in 10% of the families. Novel classification framework of all 140 epilepsy-related GATOR1 variants (including the variants of this study) revealed that 68% are loss-of-function pathogenic, 14% are likely pathogenic, 15% are variants of uncertain significance and 3% are likely benign. Our data emphasize the increasingly important role of GATOR1 genes in the pathogenesis of focal epilepsies (>180 probands to date). The GATOR1 phenotypic spectrum ranges from sporadic early-onset epilepsies with cognitive impairment comorbidities to familial focal epilepsies, and SUDEP.

27 August 2016 in Molecular Syndromology
Verified
Journal Article
Open access
PDF file
EPElena Parrini
Elena Parrini
VCValerio Conti
Valerio Conti
WDWilliam B. Dobyns
William B. Dobyns
RGRenzo Guerrini
Renzo Guerrini
Malformations of cortical development (MCD) represent a major cause of developmental disabilities, severe epilepsy, and reproductive disadvantage. Genes that have been associated to MCD are mainly involved in cell proliferation and specification, neuronal migration, and late cortical organization. Lissencephaly-pachygyria-severe band heterotopia are diffuse neuronal migration disorders causing severe global neurological impairment. Abnormalities of the LIS1, DCX, ARX, RELN, VLDLR, ACTB, ACTG1, TUBG1, KIF5C, KIF2A, and CDK5 genes have been associated with these malformations. More recent studies have also established a relationship between lissencephaly, with or without associated microcephaly, corpus callosum dysgenesis as well as cerebellar hypoplasia, and at times, a morphological pattern consistent with polymicrogyria with mutations of several genes (TUBA1A, TUBA8, TUBB, TUBB2B, TUBB3, and DYNC1H1), regulating the synthesis and function of microtubule and centrosome key components and hence defined as tubulinopathies. MCD only affecting subsets of neurons, such as mild subcortical band heterotopia and periventricular heterotopia, have been associated with abnormalities of the DCX, FLN1A, and ARFGEF2 genes and cause neurological and cognitive impairment that vary from severe to mild deficits. Polymicrogyria results from abnormal late cortical organization and is inconstantly associated with abnormal neuronal migration. Localized polymicrogyria has been associated with anatomo-specific deficits, including disorders of language and higher cognition. Polymicrogyria is genetically heterogeneous, and only in a small minority of patients, a definite genetic cause has been identified. Megalencephaly with normal cortex or polymicrogyria by MRI imaging, hemimegalencephaly and focal cortical dysplasia can all result from mutations in genes of the PI3K-AKT-mTOR pathway. Postzygotic mutations have been described for most MCD and can be limited to the dysplastic tissue in the less diffuse forms.

16 June 2016 in JCI Insight
Verified
Journal Article
Open access
PDF file
GMGhayda Mirzaa
Ghayda Mirzaa
ATAndrew E. Timms
Andrew E. Timms
VCValerio Conti
Valerio Conti
EBEvan August Boyle
Evan August Boyle
KGKatta M. Girisha
Katta M. Girisha
WDWilliam B. Dobyns
William B. Dobyns
Mosaicism is increasingly recognized as a cause of developmental disorders with the advent of next-generation sequencing (NGS). Mosaic mutations of PIK3CA have been associated with the widest spectrum of phenotypes associated with overgrowth and vascular malformations. We performed targeted NGS using 2 independent deep-coverage methods that utilize molecular inversion probes and amplicon sequencing in a cohort of 241 samples from 181 individuals with brain and/or body overgrowth. We identified PIK3CA mutations in 60 individuals. Several other individuals ( n = 12) were identified separately to have mutations in PIK3CA by clinical targeted-panel testing ( n = 6), whole-exome sequencing ( n = 5), or Sanger sequencing ( n = 1). Based on the clinical and molecular features, this cohort segregated into three distinct groups: (a) severe focal overgrowth due to low-level but highly activating (hotspot) mutations, (b) predominantly brain overgrowth and less severe somatic overgrowth due to less-activating mutations, and (c) intermediate phenotypes (capillary malformations with overgrowth) with intermediately activating mutations. Sixteen of 29 PIK3CA mutations were novel. We also identified constitutional PIK3CA mutations in 10 patients. Our molecular data, combined with review of the literature, show that PIK3CA -related overgrowth disorders comprise a discontinuous spectrum of disorders that correlate with the severity and distribution of mutations.

1 December 2016 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
RMRikke S. Møller
Rikke S. Møller
SWSarah Weckhuysen
Sarah Weckhuysen
MCMathilde Chipaux
Mathilde Chipaux
EMElise Marsan
Elise Marsan
VTValérie Taly
Valérie Taly
SBStéphanie Baulac
Stéphanie Baulac
Objective: To assess the prevalence of somatic MTOR mutations in focal cortical dysplasia (FCD) and of germline MTOR mutations in a broad range of epilepsies. Methods: We collected 20 blood-brain paired samples from patients with FCD and searched for somatic variants using deep-targeted gene panel sequencing. Germline mutations in MTOR were assessed in a French research cohort of 93 probands with focal epilepsies and in a diagnostic Danish cohort of 245 patients with a broad range of epilepsies. Data sharing among collaborators allowed us to ascertain additional germline variants in MTOR. Results: We detected recurrent somatic variants (p.Ser2215Phe, p.Ser2215Tyr, and p.Leu1460Pro) in the MTOR gene in 37% of participants with FCD II and showed histologic evidence for activation of the mTORC1 signaling cascade in brain tissue. We further identified 5 novel de novo germline missense MTOR variants in 6 individuals with a variable phenotype from focal, and less frequently generalized, epilepsies without brain malformations, to macrocephaly, with or without moderate intellectual disability. In addition, an inherited variant was found in a mother–daughter pair with nonlesional autosomal dominant nocturnal frontal lobe epilepsy. Conclusions: Our data illustrate the increasingly important role of somatic mutations of the MTOR gene in FCD and germline mutations in the pathogenesis of focal epilepsy syndromes with and without brain malformation or macrocephaly.